Ovarian biology is getting quite a bit of attention lately. And rightfully so given the large potential impact innovation in this space can have on the lives of literally every single woman on this planet. So it truly is about time we spend some time on ovarian health here on this blog, share an overview and some insights into the space with…
Celmatix, a New York-based pre-clinical stage biotech company focused on ovarian biology, has announced today that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec, has progressed into hit-identification. It may still be early in the process, but what this milestone essentially means is that Celmatix, Evotec and pharma leader Bayer, who formed a “PCOS alliance” around…
BioInnovation Institute (BII), a non-for profit Foundation known for incubating and advancing world-class life science research, has received a grant from the Bill & Melinda Gates Foundation to accelerate efforts to discover translational world-class research to identify new technologies and solutions that can improve the health of women and girls across the world, including low-income countries. The grant supports BII’s vision to strengthen the…
Gameto, a biotechnology startup solving the problem of accelerated ovarian aging to change the trajectory of women’s health and equality, today announced that it has raised a $20M in Series A funding led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures, Robert Nelsen and Anne Wojcicki. Gameto also raised $3M in Seed funding in March 2020 from a range of notable investors…
Mirvie, a pioneer in predicting unexpected pregnancy complications, has announced the publication of a study in Nature proving the proprietary Mirvie RNA platform is first to predict unexpected complications by revealing the underlying biology of each pregnancy. The research analyzed the largest and most diverse dataset of maternal transcriptomes to date. The platform opens a new window into pregnancy health for women to act…
ObsEva has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The biotech company develops and commercializes novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment…
ObsEva, a biotech company focused on women’s reproductive health has appointed Will Brown as Chief Financial Officer and member of the company’s Executive Committee, effective January 1, 2022. Will Brown is a Certified Public Accountant with deep experience in capital markets, accounting, and finance. Mr. Brown joins ObsEva from Altimmune, Inc. (NASDAQ: ALT) where he served as Chief Financial Officer and was…
Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, has been awarded a two-year, $4.9M grant from the Bill & Melinda Gates Foundation to support a global women’s health initiative. The grant is part of a Gates Foundation initiative aimed at accelerating emerging opportunities to advance the field of contraceptive drug discovery. The emphasis of this initiative…
